LabCorp launches new neutralizing antibody test for COVID-19
(Reuters) - LabCorp launched a new test on Thursday to assess the ability of antibodies in patient plasma to inhibit the novel coronavirus.
Information from the test on the ability of antibodies to fight viruses could be used in the development of COVID-19 vaccines, the company said.
The test, called the neutralizing antibody test, would be available to biopharmaceutical companies, hospitals, blood banks, and other blood plasma screening facilities.
According to the Mayo Clinic, neutralizing antibodies are associated with protective immunity against re-infection for many infectious pathogens.
The test could be used to screen serum collected from recovered COVID-19 patients for preventive and therapeutic use, the company said.
The company released its COVID-19 tests to workplaces last month and also offers laboratory tests and antibody blood tests to determine if a person has ever been infected, as well as kits that people can use to send their own collected nasal swab samples at home .
(Reporting by Manojna Maddipatla in Bengaluru; editing by Aditya Soni)
You should check here to buy the best price guaranteed products.
SALT Agreement Could Bring Two-Year Repeal of Limit
Cardano’s Ada Wants to Solve Some of Crypto’s Biggest Challenges
Aly Raisman wants to bring hope to sexual abuse survivors
Ronda Rousey Gives Birth, Welcomes First Baby With Travis Browne
Jade Bird: Prototype
'Lots of talking': Thunberg's pessimism in Milan